Company news
Vcanbio Cell & Gene Engineering Corp., Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
(600645)"Vcanbio Cell & Gene Engineering Corp., Ltd."Report for Q3 2026
October 29, 2026
(600645)"Vcanbio Cell & Gene Engineering Corp., Ltd."Notice on Convening the 2nd Extraordinary General Meeting in 2026
October 29, 2026
(600645)"Vcanbio Cell & Gene Engineering Corp., Ltd."Announcement on Resolutions of the 4th Extraordinary Meeting of the 12th Board of Directors
October 29, 2026
(600645)"Vcanbio Cell & Gene Engineering Corp., Ltd."Announcement on Re-appointment of Accounting Firm
October 29, 2026
(600645)"Vcanbio Cell & Gene Engineering Corp., Ltd."Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
October 28, 2026
(600645)"Vcanbio Cell & Gene Engineering Corp., Ltd."Indicative Announcement on Convening the 1st Extraordinary General Meeting in 2026
October 22, 2026
(600645)"Vcanbio Cell & Gene Engineering Corp., Ltd."Notice on Convening the 1st Extraordinary General Meeting in 2026
October 12, 2026
(600645)"Vcanbio Cell & Gene Engineering Corp., Ltd."Announcement on Resolutions of the 3rd Extraordinary Meeting of the 12th Board of Directors
October 12, 2026
(600645)"Vcanbio Cell & Gene Engineering Corp., Ltd."Announcement on Progress in Using Temporarily Idle Raised Funds for Cash Management
October 12, 2026
(600645)"Vcanbio Cell & Gene Engineering Corp., Ltd."Announcement on Extension of the Raised Funds Investment Project "Development of Tumor Marker Diagnostic Reagents"
October 12, 2026
(600645)"Vcanbio Cell & Gene Engineering Corp., Ltd."Announcement on Change of Certain Raised Funds Investment Projects and Implementation of Raised Funds Investment Projects via Providing Loans to Controlled Subsidiary with Raised Funds
October 12, 2026
(600645)"Vcanbio Cell & Gene Engineering Corp., Ltd."Announcement on Change of Business Scope and Amendment to the Articles of Association
October 12, 2026
(600645)"Vcanbio Cell & Gene Engineering Corp., Ltd."Announcement on Redemption upon Maturity of Cash Management Products Purchased with Idle Raised Funds
October 8, 2026
Announcement on Measures in the Form of Warning Letters Received by the Company and Relevant Persons
September 15, 2026
Announcement on Attending the 2026 Online Collective Reception Day for Investors of Listed Companies in Tianjin Jurisdiction and Semi-annual Performance Briefing
August 27, 2026
Announcement on Reply to Letter of Supervision and Inquiry on Information Disclosure of 2025 Annual Report
July 30, 2026
Announcement on Progress in Wholly-owned Subsidiary's Clinical Trial for VUM02 Injection
July 17, 2026
Announcement on Progress in Redemption of Temporarily Idle Raised Funds Used for Cash Management upon Expiration and Continuously Conducting Cash Management
July 1, 2026
Announcement on Convening the 2025 Annual Performance Briefing
June 17, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 18, 2026
Announcement on Return of Raised Funds Temporarily Used to Supplement Current Capital
May 15, 2026
Indicative Announcement on Convening the 2025 Annual General Meeting
May 12, 2026
Announcement on 2025 Annual Profit Distribution Plan
April 24, 2026
Announcement on Progress in Wholly-owned Subsidiary’s Clinical Trial for VUM02 Injection
April 21, 2026
Announcement on Progress in Using Temporarily Idle Raised Funds for Cash Management
April 1, 2026
Announcement on Redemption of Idle Raised Funds Used for Cash Management upon Maturity
March 31, 2026
Announcement on Subsidiary’s Receipt of a Medical Device Registration Certificate
March 1, 2026
with the University of Chinese Academy of Sciences Education Foundation and the Progress in Hosting the Vcanbio Life Sciences Award
December 25, 2025
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
December 15, 2025
Indicative Announcement on Convening the 2nd Extraordinary General Meeting in 2025
December 10, 2025
Announcement on Canceling the Board of Supervisors and Amending the "Articles of Association"
November 27, 2025
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
November 14, 2025
Indicative Announcement on Convening the 1st Extraordinary General Meeting in 2025
November 10, 2025
Announcement on Wholly-owned Subsidiary Obtaining Notice of Approval for Drug Clinical Trials
October 30, 2025
Report for Q3 2025
October 29, 2025
Announcement on the Return of Idle Raised Funds for Cash Management to the Dedicated Fundraising Account
September 25, 2025
Announcement on Attending 2025 Online Collective Reception Day for Investors of Listed Companies in Tianjin Jurisdiction and Semi-annual Report Performance Briefing
September 4, 2025
Special Report on Semi-annual Deposit and Actual Use of Raised Funds in 2025
August 27, 2025
Announcement on Wholly-owned Subsidiary Obtaining Notice of Acceptance for Application of Drug Clinical Trials
August 4, 2025
Announcement on Resolutions of the 20th Extraordinary Meeting of the 11th Board of Directors
July 29, 2025
Announcement on Resolutions of the 19th Extraordinary Meeting of the 11th Board of Directors
July 9, 2025
Announcement on Extension of Pledge of Partial Equity of Persons Acting in Concert with Controlling Shareholders
June 27, 2025
Announcement on Returning Idle Raised Funds Used for Cash Management to Special Account for Raised Funds
June 24, 2025
Announcement on Wholly-owned Subsidiary Obtaining Notice of Acceptance of Application for Drug Clinical Trial
June 23, 2025
Announcement on Resolution of the 9th Extraordinary Meeting of the 11th Board of Supervisors
May 21, 2025
Announcement on Resolution of the 2024 Annual General Meeting
May 20, 2025
Announcement on Convening the 2024 Annual Performance Briefing
May 14, 2025
Announcement on Change of Accounting Policies
April 24, 2025
Announcement on Returning Idle Raised Funds Used for Temporarily Supplementing Current Capital
April 23, 2025
Announcement on the Resignation of Deputy General Manager and Secretary of the Board of Directors
April 9, 2025